JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB237640

Rituximab ELISA Kit

Be the first to review this product! Submit a review

|

(0 Publication)

Rituximab ELISA Kit is a sandwich ELISA designed to quantify free Rituximab with a sensitivity of 3 ng/mL.

- Colorimetric sandwich ELISA - 450 nm readout - works on any plate reader
- Can be used for pharmacokinetic (PK) studies
- Wide dynamic range - quantifies 3 - 100 ng/mL
- For Research Use Only - Not intended for diagnostic use
1 Images
Sandwich ELISA - Rituximab ELISA Kit (AB237640)
  • sELISA

Supplier Data

Sandwich ELISA - Rituximab ELISA Kit (AB237640)

Example of Rituximab standard curve.

Typical Standard Curve : This standard curve is for demonstration only. A standard curve must be run with each assay.

Key facts

Detection method

Colorimetric

Sample types

Plasma, Serum

Reacts with

Human

Assay type

Quantitative

Sensitivity

= 3 ng/mL

Range

3 - 100 ng/mL

Assay Platform

Microplate

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column
style
left-column

Product details

Note: Rituximab ELISA kit ab237640 is intended for Research Use Only, not for use in diagnostic procedures.

This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Rituximab in the sample or standard. Results of samples can be determined directly using the standard curve.

This assay measures only free Rituximab.

This product is manufactured by BioVision, an Abcam company and was previously called E4371 BioSim™ Rituximab (Human) ELISA Kit. E4371-100 is the same size as the 96 test size of ab237640.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

style
left-column

Precision

[ { "reproducibilityType": "Inter", "sample": "Overall", "replicates": 0, "mean": null, "standardDeviation": null, "coefficientOfVariability": "< 30" }, { "reproducibilityType": "Intra", "sample": "Overall", "replicates": 0, "mean": null, "standardDeviation": null, "coefficientOfVariability": "< 30" } ]
style
left-column

What's included?

{ "values": { "96Test": { "sellingSize": "96 Test", "publicAssetCode":"ab237640-96Test", "assetComponentDetails": [ { "size":"1 x 1 mL", "name":"Rituximab Standard S4", "number":"AB237640-CMP07", "productcode":"" }, { "size":"1 x 12 mL", "name":"Stop Solution", "number":"AB237640-CMP12", "productcode":"" }, { "size":"1 x 1 mL", "name":"Rituximab Standard S5", "number":"AB237640-CMP08", "productcode":"" }, { "size":"1 x 12 mL", "name":"TMB substrate", "number":"AB237640-CMP14", "productcode":"" }, { "size":"1 x 1 mL", "name":"Rituximab Standard S2", "number":"AB237640-CMP04", "productcode":"" }, { "size":"1 x 1 mL", "name":"Rituximab Standard S7", "number":"AB237640-CMP10", "productcode":"" }, { "size":"1 x 1 mL", "name":"Rituximab Standard S6", "number":"AB237640-CMP09", "productcode":"" }, { "size":"1 x 1 mL", "name":"Rituximab Standard S3", "number":"AB237640-CMP05", "productcode":"" }, { "size":"1 x 1 mL", "name":"Rituximab Standard S1", "number":"AB237640-CMP03", "productcode":"" }, { "size":"1 x 50 mL", "name":"Assay Buffer", "number":"AB237640-CMP01", "productcode":"" }, { "size":"1 x 50 mL", "name":"Wash buffer (20X)", "number":"AB237640-CMP15", "productcode":"" }, { "size":"1 x 12 mL", "name":"HRP-conjugate Probe", "number":"AB237640-CMP02", "productcode":"" }, { "size":"2 x 1 Unit", "name":"Plate sealers", "number":"AB237640-CMP06", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Micro ELISA Plate", "number":"AB237640-CMP13", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
+4°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Rituximab also known as anti-CD20 is a monoclonal antibody that targets the CD20 protein expressed on the surface of B cells. The CD20 protein is a non-glycosylated phosphoprotein with a mass of approximately 33 to 37 kilodaltons. It is expressed in both normal and malignant B cells from the pre-B-cell stage through the mature B-cell stage. The protein is absent in pro-B cells and plasma cells which helps in the specific targeting of B cells without affecting the stem cells or other immune cells.
Biological function summary

Rituximab depletes B cells by inducing cell lysis through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab’s binding to CD20 leads to B cell apoptosis. As part of the immune system B cells produce antibodies; hence B cell depletion affects humoral immunity. However this depletion allows for the reduction of abnormal B cells in conditions like cancer and autoimmune diseases where aberrant B cell activity plays a harmful role.

Pathways

CD20 does not belong to a multi-component signaling complex but plays a role in calcium signaling in B cells. It modulates calcium influx which is critical for B cell activation and regulation. The pathways involving CD20 are associated with B-cell receptor signaling an essential mechanism regulating B cell survival and proliferation. Other proteins like SYK and BLNK are involved in the extended signaling cascade triggered by B-cell receptor activation.

Rituximab plays an important role in the treatment of B-cell non-Hodgkin lymphomas and rheumatoid arthritis. It targets and removes malignant B cells in lymphoma offering an effective therapy alongside traditional chemotherapies. In rheumatoid arthritis rituximab reduces B cell-mediated inflammation and tissue damage. Rituximab's specificity for CD20 allows it to reduce disease-associated B cells without destroying all B cells minimizing unintended consequences on the immune system.
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

See full target information Rituximab
style
left-column
style
left-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
style
left-column
websiteProtocolBooklet
en
style
right-column

Associated Products

Select an associated product type
Alternative Product
Assay Kits

AB237654

anti-Rituximab ELISA Kit

elisa-kits

rituximab-elisa-kit-ab237654

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com